Children with Eczema Struggle More with Comorbid ADHD Symptoms
New data suggest children with atopic dermatitis and comorbid ADHD are nearly 3 times more likely to struggle with memory compared to those with just ADHD.
Read More
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Data show significant maternal and fetal risks in cases when pregnant women are diagnosed with hidradenitis suppurativa. A researcher discusses opportunities to learn more.
Analysis: Pediatric Isotretinoin Use Not Linked to Shorter Adult Height
Isotretinoin was actually linked to a taller adult height among those who took it to treat acne in childhood versus doxycycline, in a new study.
Pediatric Contact Dermatitis Allergens Vary by Age, Sex, Race
New data show sensitization among children with allergic contact dermatitis may be significantly influenced by their age and gender, among other demographic details.
Andrew F. Alexis, MD, MPH: ADORING Trials, Tapinarof Cream, and Improving Skin of Color Research Representation
Alexis discusses clinical and demographic hurdles in treating skin of color for conditions like atopic dermatitis, and the potential of research like that being done in tapinarof cream 1%.
Building a Psoriasis Knockout Regimen Around Risankizumab, with Andrew Blauvelt, MD, MBA
Blauvelt discusses the future research of higher-dose risankizumab for patients with psoriasis—and why it may be "disruptive in the treatment space."
Children with Atopic Dermatitis May Be Shorter in Height
New global data suggest children with moderate to severe atopic dermatitis may experience stunted growth due to the effect of their disease on sleep, as well as use of certain therapies.
Joel Gelfand, MD, MSCE: Phototherapy Utility in Psoriasis
Gelfand discusses the convenience of phototherapy, and how its efficacy may complement biologic regimens in patients with psoriasis.
Pediatric Hidradenitis Suppurativa Severity not Linked to Obesity
New data from the Mayo Clinic show high BMI does not correlate with severe hidradenitis suppurativa in affected children and adolescents.
Johnson & Johnson Submits Guselkumab Application to FDA for Ulcerative Colitits
The submission could grant guselkumab its third indication, after being approved by the FDA for psoriasis and psoriatic arthritis.
Risankizumab and the KNOCKOUT Study, with Andrew Blauvelt, MD, MBA
Blauvelt discusses the impetus for his phase 2 trial looking at the ability to mitigate pivotal psoriasis memory T cells with risankizumab.
Tapinarof Cream Significantly Improves Atopic Dermatitis Regardless of Skin Color
In a phase 3 trial that featured approximately half of participants with skin of color, tapinarof cream 1.0% provided consistent benefit for patients identified as White, Black, or Asian.
Brian Kim, MD: Pushing Dermatology Forward and Alys Pharmaceuticals
Kim discusses the state of dermatology innovation and applied care, as well as his involvement in a new company in the space.
Ruxolitinib Cream Improves Itch, Sleep, Skin Pain in Children with Atopic Dermatitis
A secondary analysis from TRuE-AD3 shows ruxolitinib cream significantly benefits pediatric atopic dermatitis patient-reported outcomes.
Oral Upadacitinib Significantly Reduces Facial, Total Nonsegmental Vitiligo Through 52 Weeks
Thierry Passeron, MD, PhD, discusses the potential benefit of upadacitinib as an oral systemic therapy in patients with nonsegmental vitiligo.
Preservative, Surfactant Allergens Frequently Found in Infant Skincare Products
Data presented at AAD 2024 hopes to clarify allergen exposure risks during infancy that may increase risk of allergic contact dermatitis.
Brian S. Kim, MD: Prioritizing the Patient in Dermatology Innovation
The pioneer in neuroimmune research and itch physiology discusses how treatment innovation has evolved dermatology—and what still needs to be changed in practice.
LITE Study Shows Similar Efficacy Between At-Home, In-Office Psoriasis Phototherapy
Phototherapy is consistently beneficial for patient-reported and clinical outcomes regardless of the location, according to late-breaking data at AAD 2024.
High Risankizumab Induction Dose Rapidly Clears Psoriasis, Reduces Resident Memory Cells
Data from the phase 2 KNOCKOUT study show risankizumab's sustained benefit in reducing memory cells over 52 weeks in psoriasis patients.
Maternal Hidradenitits Suppurativa Linked to Neonatal Mortality, Pediatric Hospitalization Risk
A national cohort analysis presented at AAD 2024 showed a significant link between maternal HS exposure and poor health outcomes among children.
Breakthroughs in Pediatric Atopic Dermatitis and More, with Peter A. Lio, MD
Lio reviews a field now teeming with FDA-approved options and candidates throughout early-age eczema, psoriasis and more.
Black Pediatric Patients with Hidradenitits Suppurativa Report Worse Income Status, Health Risks
New data presented at AAD 2024 highlights challenges in financial status, insurance and comorbidities among black pediatric patients with HS.
Nanette B. Silverberg, MD: Uncovering Molluscum Epidemiology
With a couple of first-time therapies available for molluscum, Silverberg is interested in learning more about the disease's causes and manifestations.
Addressing Benzoyl Peroxide Concerns and Responsible Antibiotic Prescribing
James Q. Del Rosso, DO, discusses the recent report of benzene risk in benzoyl peroxide, as well as the need for active antibiotic monitoring in dermatology.
Amy Paller, MD: Long-Term Outlook for EB, Ichthyosis and Netherton Syndrome Treatment
With drug breakthroughs reaching epidermolysis bullosa, Paller considers what may come next for other rare skin diseases.
3 Tried and True Methods of Pediatric Eczema Management
Lawrence Eichenfield, MD, reviews prescription and at-home care strategies for pediatric atopic dermatitis, as well as the best measures of disease monitoring.
Celebrating 30 Years of Camp Discovery, with Susan Boiko, MD
Boiko discusses the annual weeklong summer camp for children and adolescents with skin diseases to make connections, experience camp with the support of volunteer specialists, and find comfort with their condition.
How Gene and Cell Therapy Is Developing in Dermatology
Peter Marinkovich, MD, reflects on the significant growth in advanced therapy development, particularly in rare skin diseases.
Reviewing New Molluscum Therapies, with Nanette B. Silverberg, MD
The FDA approved the first 2 therapies to treat molluscum contagiosum in the last year. Silver explains how it's provided more than just treatment options.
Gene, Cell Therapies and Advanced Rare Disease Talk at AAD 2024
Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.